Aker BioMarine (AKBM) Q1 2026 earnings summary

Executive summary

• Group revenue reached USD 57.3 million in Q1 2026, up 13% year-over-year, with adjusted EBITDA of USD 12.5 million, up 34% year-over-year.

• Human Health Ingredients segment delivered record krill oil sales, up 26% year-over-year, and overall segment revenue up 22% year-over-year.

• Consumer Health Products revenue declined 2% year-over-year, impacted by Amazon strategy changes and Epion repositioning, but EBITDA margin improved due to lower SG&A expenses and private label growth.

• Net loss from continued operations was USD -2.4 million, with total net loss at USD -2.7 million for the quarter.

• Refinanced NOK 1,600 million bond with a new USD 175 million term loan.

Financial highlights

• Gross margin improved to 45% from 43.6% in Q1 2025, driven by higher Superba sales.

• Human Health Ingredients gross margin at 61%, slightly down from 62% last year; Consumer Health Products stable at 24%.

• Adjusted EBITDA was USD 12.5 million, up from USD 9.4 million in Q1 last year.

• Net financial result was negative NOK 2.7 million, slightly improved from a year ago.

• Cash at quarter end was NOK 19.8 million (USD 33 million total available liquidity).

• Equity at quarter end was USD 141.4 million, with an equity ratio of 37%.

Outlook and guidance

• Human Health Ingredients expected to continue strong growth and improved profitability due to operational leverage and strong demand.

• Consumer Health Products anticipated to return to modest growth as one-off effects normalize.

• Company is exploring strategic alternatives for the Human Health Ingredients business, with investment banks engaged and advanced discussions for Understory asset sale.